# OnCo record lymphoma-living-infection-years-after (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/lymphoma-living-infection-years-after/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "lymphoma-living-infection-years-after" ;
  schema:name "Low antibodies and infection risk for years after anti-CD20 and bispecific antibodies"@en ;
  schema:alternateName "Hypogammaglobulinaemia after rituximab"@en, "Infection risk after CAR-T"@en, "Immunoglobulin replacement lymphoma"@en, "B-cell aplasia"@en ;
  schema:description "Treatments that remove B cells also remove the cells that make antibodies, and the effect can last for years after the last dose. Most people need nothing more than ordinary vigilance, but some need preventive antibiotics or infusions of donor antibodies, and a fever at any point in that period is an emergency rather than a nuisance."@en ;
  schema:url <https://onco.cc/terms/lymphoma-living-infection-years-after/> ;
  schema:dateModified "2026-10-01"^^xsd:date ;
  schema:citation <https://lymphoma-action.org.uk/information-and-support/lymphoma-treatment/immunoglobulin-replacement-therapy>, <https://lymphoma-action.org.uk/information-and-support/side-effects-lymphoma-and-treatment/infections-risk-and-prevention>, <https://lymphoma-action.org.uk/information-and-support/lymphoma-treatment/car-t-cell-therapy>, <https://lymphoma-action.org.uk/information-and-support/side-effects-lymphoma-and-treatment/neutropenia-low-neutrophils>, <https://assets.publishing.service.gov.uk/media/5e18a52940f0b65dc1918763/Greenbook_chapter_7_Immunsing_immunosupressed.pdf>, <https://www.nice.org.uk/guidance/cg151> ;
  onco:cancers <https://onco.cc/cancers/non-hodgkin-lymphoma/>, <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/follicular-lymphoma/>, <https://onco.cc/cancers/mantle-cell-lymphoma/>, <https://onco.cc/cancers/marginal-zone-lymphoma/>, <https://onco.cc/cancers/malt-lymphoma/>, <https://onco.cc/cancers/splenic-marginal-zone-lymphoma/>, <https://onco.cc/cancers/nodal-marginal-zone-lymphoma/>, <https://onco.cc/cancers/waldenstrom/>, <https://onco.cc/cancers/primary-mediastinal-b-cell-lymphoma/>, <https://onco.cc/cancers/hodgkin-lymphoma/> ;
  onco:technologies <https://onco.cc/technologies/car-t/>, <https://onco.cc/technologies/bispecific-antibody/> ;
  onco:terms <https://onco.cc/terms/hypogammaglobulinaemia/>, <https://onco.cc/terms/lymphoma-tx-immunoglobulin-replacement/>, <https://onco.cc/terms/lymphoma-tx-pjp-and-infection-prophylaxis/>, <https://onco.cc/terms/neutropenia/>, <https://onco.cc/terms/febrile-neutropenia/>, <https://onco.cc/terms/lymphoma-living-vaccinations/> .